A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Johnson & Johnson
- 09 Jan 2019 Planned End Date changed from 29 Jul 2021 to 29 Sep 2021.
- 09 Jan 2019 Planned initiation date changed from 4 Jan 2019 to 4 Mar 2019.
- 14 Nov 2018 Planned End Date changed from 30 Apr 2021 to 29 Jul 2021.